Gabrielle Agin-Liebes, PhD

Title(s)Postdoctoral Scholar, Psychiatry
SchoolSchool of Medicine
Phone--
ORCID ORCID Icongagin-liebes Additional info
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Gabby is a licensed clinical psychologist. She is currently a National Institute on Drug Abuse T32 Research Fellow in Substance Use Disorders Treatment and Services Research at UCSF within the Psychedelics Divisions of Neuroscape. Her research explores transdiagnostic psychological mechanisms (e.g., emotion regulation, metacognition, self-transcendence) underlying the therapeutic outcomes in treatments of mood, anxiety and substance use disorders. She also conducts qualitative research on psychotherapy-related change processes. She has over 11 years of experience working as a therapist and investigator on FDA-approved clinical trials with psilocybin at New York University, Yale and UC San Francisco (UCSF). Her research applies quantitative and qualitative methodologies to study the role of emotion regulation and metacognitive processes (e.g., mindfulness/self-compassion and reappraisal) targeted by psychedelic-assisted therapies for the treatment of addiction, existential distress, and PTSD. Her 2020 study, which found that psilocybin-assisted therapy was associated with improvements 4.5 years after treatment, garnered media attention in several global news outlets including Time, Newsweek, and CNN.
    Collapse Websites

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Faculty Mentoring

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Prospective examination of the therapeutic role of psychological flexibility and cognitive reappraisal in the ceremonial use of ayahuasca. J Psychopharmacol. 2022 Mar; 36(3):295-308. Agin-Liebes G, Zeifman R, Luoma JB, Garland EL, Campbell WK, Weiss B. PMID: 35253514.
      View in: PubMed   Mentions:
    2. Comment and Response: (Lugo-Radillo & Cortez-Lopez, 2020) Long-Term Amelioration of OCD Symptoms in a Patient with Chronic Consumption of Psilocybin-Containing Mushrooms. J Psychoactive Drugs. 2022 Jan 27; 1-4. Fitzpatrick CM, Anderson BT, Agin-Liebes G, Guydish J. PMID: 35083957.
      View in: PubMed   Mentions:
    3. Assessing the Acceptability of Yoga Among Patients with and without Chronic Pain Enrolled in a Licensed Opioid Treatment Program. Int J Yoga Therap. 2022 Jan 01; 32(2022). Ahmadi E, Evans C, Agin-Liebes G, Tompkins DA. PMID: 35377949.
      View in: PubMed   Mentions:
    4. Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach. Curr Top Behav Neurosci. 2021 Nov 23. Agin-Liebes G, Davis AK. PMID: 34811715.
      View in: PubMed   Mentions:
    5. Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States. J Psychoactive Drugs. 2021 Sep 01; 1-10. Davis AK, Agin-Liebes G, España M, Pilecki B, Luoma J. PMID: 34468293.
      View in: PubMed   Mentions:    Fields:    
    6. Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone. Drug Alcohol Depend. 2021 09 01; 226:108869. Agin-Liebes G, Huhn AS, Strain EC, Bigelow GE, Smith MT, Edwards RR, Gruber VA, Tompkins DA. PMID: 34216862.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Participant Reports of Mindfulness, Posttraumatic Growth, and Social Connectedness in Psilocybin-Assisted Group Therapy: An Interpretive Phenomenological Analysis. Journal of Humanistic Psychology. 2021; (0022167821). Agin-Liebes, G., Ekman, E., Anderson, B., Malloy, M., Haas, A., & Woolley, J. View Publication.
    8. Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes. ACS Pharmacol Transl Sci. 2021 Apr 09; 4(2):543-552. Agin-Liebes G, Haas TF, Lancelotta R, Uthaug MV, Ramaekers JG, Davis AK. PMID: 33860184; PMCID: PMC8033766.
      View in: PubMed   Mentions:
    9. Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer. ACS Pharmacol Transl Sci. 2021 Apr 09; 4(2):553-562. Ross S, Agin-Liebes G, Lo S, Zeifman RJ, Ghazal L, Benville J, Franco Corso S, Bjerre Real C, Guss J, Bossis A, Mennenga SE. PMID: 33860185; PMCID: PMC8033770.
      View in: PubMed   Mentions:
    10. Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis. J Humanist Psychol. 2020; 4(57):354-88. Belser AB, Agin-Liebes G, Swift TC, Terrana S, Devenot N, Friedman HL, Guss J, Bossis A, Ross S.
    11. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine. 2020 Oct; 27:100538. Anderson BT, Danforth A, Daroff PR, Stauffer C, Ekman E, Agin-Liebes G, Trope A, Boden MT, Dilley PJ, Mitchell J, Woolley J. PMID: 33150319; PMCID: PMC7599297.
      View in: PubMed   Mentions: 7  
    12. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020 02; 34(2):155-166. Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Ponté KL, Guss J, Bossis AP, Grigsby J, Fischer S, Ross S. PMID: 31916890.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    13. Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy. Front Pharmacol. 2018; 9:256. Malone TC, Mennenga SE, Guss J, Podrebarac SK, Owens LT, Bossis AP, Belser AB, Agin-Liebes G, Bogenschutz MP, Ross S. PMID: 29666578; PMCID: PMC5891594.
      View in: PubMed   Mentions: 5  
    14. Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress. J Humanist Psychol. 2017; 5(57):488-519. Swift TC*, Belser AB*, Agin-Liebes G*, Devenot N, Terrana S, Friedman HL, Guss J, Bossis AP, Ross S. [*denotes co-first authorship].
    15. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016 12; 30(12):1165-1180. Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL. PMID: 27909164; PMCID: PMC5367551.
      View in: PubMed   Mentions: 143     Fields:    Translation:HumansCTClinical Trials
    16. The child and adolescent mental health studies program (CAMS) at New York University. Neuropsychiatrie de l'enfance et de l'adolescence. 2012; 5(60):296. Shatkin J, Agin-Liebes G.
    Gabrielle's Networks
    Concepts (35)
    Derived automatically from this person's publications.
    _
    Co-Authors (8)
    People in Profiles who have published with this person.
    _
    Similar People (59)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _